Sign in Subscribe
Cancer

Immunophotonics Completes Phase 1b/2a Clinical Trial of IP-001 for Advanced Solid Tumors

Strategic Insights

— 1 min read

Immunophotonics, a clinical-stage biotech company, has announced the completion of the INJECTABL-1 multicenter Phase 1b/2a clinical trial of its proprietary glycan polymer, IP-001, for advanced solid tumors. The trial, conducted in five countries, aimed to evaluate the systemic immune-mediated anti-cancer effects of IP-001 following tumor ablation. The company reports that early signals are positive, and it plans to continue assessing the efficacy of this novel therapy.

Key Takeaways:

  • The INJECTABL-1 trial enrolled 41 patients across three distinct cancer types: colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma.
  • The trial was designed to evaluate the systemic immune-mediated anti-cancer effects of IP-001 following tumor ablation, which is an approved and well-established procedure readily available at most hospitals and clinics.
  • IP-001 is a novel immunotherapy administered by injection into the ablation zone, working by retaining tumor debris and activating the patient's immune system for systemic tumor surveillance.
  • Immunophotonics has expanded clinical collaborations to further assess the efficacy of its novel asset, IP-001, with the company's co-founder and CEO, Lu Alleruzzo, stating that early signals are positive.
  • The trial was conducted in France, Germany, Switzerland, the UK, and the US, with the Principal Investigator, Prof. Dr. Markus Jörger, commenting on the completion of the last patient's treatment.
  • Immunophotonics is committed to leading the field of Interventional Immuno-Oncology, aiming to reduce tumor recurrence after standard-of-care local ablation therapy.
  • The company's proprietary glycan polymer, IP-001, is designed to generate tumor antigen depots, act as a potent immune stimulant, and induce immunological responses to eradicate cancer.

Statistics:

  • 41 patients were enrolled in the INJECTABL-1 multicenter Phase 1b/2a clinical trial.
  • The trial was conducted across five countries.
  • Early signals are positive for the efficacy of IP-001, according to Immunophotonics' co-founder and CEO, Lu Alleruzzo.

Sources:

  • Immunophotonics Press Release, "Immunophotonics completes patient enrollment in INJECTABL-1 study evaluating IP-001 for advanced solid tumors", July 31, 2025.
  • Immunophotonics Website:

Read more